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Abstract: CD200 molecule may play a role in local tumor invasion and augmenting the metastatic capacity of
squamous cell carcinoma. The objective of the study was to assess by means of flow cytometry the expression of
CD200 and its receptor, CD200R, on CD83+ monocyte-derived dendritic cells (Mo-DCs), pulsed or not with autol-
ogous tumor cell lysates (aTCL) in patients who suffer from laryngeal carcinoma in comparison to healthy donors.
The median value of CD200 mean fluorescence intensity (MFI) on the Mo-DCs pulsed with aTCL of the pa-
tients with laryngeal cancer was 61.94 and was statistically significantly higher than on the unpulsed Mo-DCs of
these patients (24.81) and healthy donors (16.63), p = 0.0034 and p = 0.0004, respectively. Median MFI score of
CD200R in specimen derived from patients with laryngeal cancer was 259.31 on Mo-DCs pulsed with aTCL,
while in unpulsed Mo-DCs was 86.74 (p = 0.0035) and on the Mo-DCs from control group it was 67.51 (p = 0.0004).
The obtained results showed a relation between the presence of laryngeal cancer and the expression of CD200
and CD200R molecules on the CD83+ Mo-DCs pulsed with autologous cancer cell lysates. This analysis may
have implications for setting new therapeutic options for cancer immunotherapy in the future. (Folia Histochemica
et Cytobiologica 2013, Vol. 51, No. 1, 59–65)
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Introduction
CD200 (formerly OX2) is a type 1a membrane protein
with two extracellular Ig superfamily domains, a single
transmembrane region, and a short cytoplasmic tail [1,
2], broadly expressed on a variety of cell types, such as
some dendritic cells, thymocytes, T and B lymphocytes,
neurons, kidney glomeruli, syncytiotrophoblasts, and
endothelial cells [3]. CD200 delivers immunoregula-
tory signals by binding to receptors expressed on mono-
cytes/myeloid cells, including monocyte-derived den-
dritic cells, and T lymphocytes. Signals delivered via
the CD200:CD200R axis were shown to play an im-
portant role in the regulation of anti-tumor immunity.
Overexpression of CD200 was found in a number of
malignancies and on cancer stem cells [4] and it was
assumed that this molecule may play roles in local tu-
mor invasion as well as augmenting the metastatic ca-
pacity of squamous cell carcinoma [5].
Laryngeal cancer is one of the most commonly
occurring malicious cancers of head and neck region,
with squamous cell carcinoma as the predominant
histologic type [6, 7]. Despite constant development,
the classical therapeutic methods, such as surgical
procedures or radiotherapy are not sufficiently effec-
tive in prolonging the survival time of cancer patients
and improving the quality of their lives [8]. There-
fore, the increasing morbidity and unsatisfactory ef-
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fects of treatment, especially in cases of advanced la-
ryngeal carcinoma, stimulate scientists and clinicians
to develop more effective therapy modalities includ-
ing immunotherapy with the use of the dendritic cells
and/or monoclonal antibodies [9].
The main aim of the present study was to assess the
expression of CD200 and CD200R on CD83+ mono-
cyte-derived dendritic cells, pulsed or not with autolo-
gous tumor cell lysates, of patients who suffer from
laryngeal cancer in comparison to healthy donors. To
the best of our knowledge, the present publication is
the first to describe the mentioned issue. The results
of our study may have implications for setting new stan-
dards for cancer immunotherapy in the future.
Material and methods
Patients and healthy controls. Forty-four male patients
treated surgically for primarily diagnosed squamous cell
carcinoma of the larynx, without preoperative treatment,
were included in the study. The diagnosis of squamous cell
carcinoma of the larynx was established by histopathology
of tumor samples. The mean age of patients was 63.23 ±
8.85 years (ranging from 47 to 76 years; median: 64.5). Ta-
ble I presents patients’ characteristics.
Peripheral blood from twelve healthy male donors, at
the mean age of 56.83 ± 10.24 (ranging from 43 to 70 years;
median: 57), was used as a control. Both in patients and
healthy donors peripheral blood WBC was within the nor-
mal range between 4 and 10 G/L.
None of the patients and controls showed signs of infec-
tion at the time of investigation and for a month before sur-
gery none had been taking drugs of known influence on the
immune system. None of the patients or healthy donors had
undergone blood transfusion. Persons with allergic diseas-
es in anamnesis were excluded from the study. The research
protocol was approved by the local Ethics Committee and
all patients gave written informed consent.
Isolation of the peripheral blood mononuclear cells. Mono-
nuclear cells (PBMCs) were separated from heparinized
venous blood of the patients and the healthy donors by den-
sity gradient centrifugation using Gradisol-L (Aqua Medi-
ca, Poland) and centrifuged for 20 minutes at 700 g. PB-
MCs were collected and washed twice in PBS without Ca2+
or Mg2+ (Biochrom, Germany). Interphase cells were
washed twice in phosphate-buffered saline (PBS) without
Ca2+ or Mg2+ (Biochrom AG, Germany) and then resus-
pended at 0.5–1 x106 cells/mL. Cell viability was checked by
Trypan Blue exclusion test (Sigma-Aldrich, Germany).
Preparation of the neoplastic cell lysates. Laryngeal cancer
tissue was obtained during surgical treatment. Tumor sam-
ples (without necrotic areas) were digested with 1 mg/mL
of type I collagenase (Biochrome AG, Germany), 1 mg/mL
of type I deoxyribonuclease (Sigma-Aldrich, Germany) and
0.1 mg/mL of hyaluronidase (Sigma-Aldrich, Germany) and
washed twice in RPMI 1640 (Biochrom, Germany). Tumor
cells were homogenized by five repeated cycles of quick
freezing (–80°C) and thawing (37°C). Large particles were
removed by centrifugation and after that supernatants were
passed through a 20 mm pore filter.
Dendritic cells generation. PBMCs were incubated with anti-
CD14 microbeads (Miltenyi-Biotec, Germany) and passed
through MACS separation columns according to the man-
ufacturer’s instructions. Viability of isolated cells was con-
firmed using Trypan Blue dye exclusion and samples with
viability less than 90% were excluded from analysis. The
CD14 positive cell population was used to prepare mono-
cyte-derived dendritic cells (Mo-DCs). After isolation, the
CD14+ cells were washed twice with phosphate-buffered
saline (PBS) and seeded into cell culture flasks. The CD14+
cells were cultured in RPMI 1640 medium (BioWhittaker,
USA) supplemented with 2% human albumin (Baxter, Aus-
tria), 100 IU/mL penicillin, 50 mg/mL streptomycin and
100 mg/mL neomycin (Sigma-Aldrich, Germany) for 2 h at
37oC and 5% CO2. After incubation, the non-adherent cells
were removed with PBS without Ca2+ and Mg2+ (Bio-
chrom, Germany). Adherent cells were grown in the ap-
propriate culture medium for 7 days. On days 1, 3 and
5 1000 IU/mL rhGM-CSF (Leukine, USA) and 500 IU/mL
rhIL-4 (Miltenyi-Biotec, Germany) were added to the cul-
tures. The cells were then divided into two equal parts and
the first part was assessed using flow cytometry method with-
out stimulation with tumor cell lysates. Tumor necrosis fac-
tor a (rhTNF-a, Strathmann, Germany) at a concentration
of 50 ng/mL and the autologous tumor cell lysates were add-
ed to the second part of cells during the last 48 hours of
culture for the maturation and pulsing of the Mo-DCs.
The Mo-DCs of healthy controls were generated as de-
scribed above; however, they were not pulsed with autolo-
gous tumor cell lysates due to the absence of cancer tissue
in this group. Generated cells were then harvested using
Trypsin/EDTA solution (Biochrom, Germany).
Flow cytometric analysis. Following monoclonal antibod-
ies (mAb) were used: anti-CD83 FITC (BD Bioscience,
USA)/anti-CD200 PE (AbD Serotec, USA) and anti-CD83
FITC (BD Bioscience, USA)/anti-CD200R PE (AbD Se-
rotec, USA). The cell phenotype characterization was per-
formed using a FACSCalibur cytometer equipped with 488-
nm argon laser (Becton Dickinson, USA) and analyzed with
CellQuest Software (Becton Dickinson, USA). We collect-
ed 300 000 of events in total. Cell debris and dead cells were
excluded from the analysis based on scatter signal.
Statistical analysis. Statistica 9 PL (Stat Soft Inc.) software
was applied to statistical analysis and Mann-Whitney U test
was used. Pearson’s linear correlation coefficient (r) was
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calculated to disclose relationships between variables. All
results are showed as means ± standard deviation (SD) and
medians. P-value less than 0.05 was considered statistically
significant.
Results
The results are presented in the form of percentage
values of the cells with the expression of a given anti-
gen and the mean fluorescence intensity (MFI), which
is the mean score of the density of an expression of
a given molecule on a cell. Figure 1 presents an ex-
ample of a three-color flow cytometry analysis of an
expression of CD200 and CD200R molecules on the
CD83+ Mo-DCs generated from patients with squa-
mous cell carcinoma of the larynx.
Our study revealed that the percentage of mono-
cyte-derived DCs with an expression of CD83 anti-
gen in patients (median: 90.54%, range 51.45–99.22%;
mean: 86.44 ± 12.18%) was statistically lower
(p = 0.0002) than in healthy donors (median 99.79%,
range 99.66–99.86%; mean: 99.79 ± 0.07%). The dif-
ferences of CD83 MFI values between the patients’
and control groups were also statistically significant
(p = 0.04); higher in patients (median: 287.49, range
213.96–628.26; mean: 334.34 ± 117.28) than in
healthy individuals (median: 224.07, range 139.72–
–276.38; mean: 212.71 ± 63.41).
The median MFI value of CD200 antigen on the
CD83+ Mo-DCs from laryngeal cancer patients, stim-
ulated with autologous tumor cell lysates, was 61.94
(range 41.65–.37; mean: 111.29 ± 95.44) and was sta-
tistically significantly higher than on the unpulsed Mo-
DCs of laryngeal cancer patients (median: 24.81; range
18.73–49.37; mean: 26.54 ± 8.62) and healthy donors
(median: 16.63, range 14.4–.47; mean: 17.99 ± 4.15),
p = 0.0034 and p = 0.0004, respectively (Figure 2).
MFI of CD200 receptor expression on CD83+
Mo-DCs among the patients with laryngeal cancer was
395.54 ± 215.89 (median: 259.31, range 188.63–
–810.35), while in the control group it was 71.18 ±
± 37.12 (median: 67.51, range 16.99–124.78). Surpris-
ingly, Mann-Whitney U test revealed that the statisti-
cal significance was exactly the same as in the case of
the CD200 MFI assessment (p = 0.0004). Median
MFI score of CD200R among the unpulsed Mo-DCs
Figure 1. An example of a three-color flow cytometry analysis of a CD200 and CD200R molecules expression on the Mo-
DCs generated from a patient with squamous cell carcinoma of the larynx. The upper dot plot shows the forward scatter/
/side scatter (FSC/SSC) distribution and the gate used to select Mo-DCs for analysis. The number in the upper right
quadrant in the dot plots represents the percentage of CD83+ CD200+ cells (down left dot plot) and the percentage of
CD83 + CD200R+ cells (down right dot plot)
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derived from persons with laryngeal cancer was 96.74 ±
± 49.18 (median: 89.23, range 8.64–171.42) and was
significantly different from those pulsed with autolo-
gous cancer cell lysates (p = 0.0035) (Figure 3).
The proportion of CD83+CD200+ cells in the
blood of laryngeal cancer patients was higher than in
healthy persons (median: 11.63%, range 6.17%–
–39.75%; mean: 13.12 ± 8.75% vs. median: 9.34%,
range 6.12–.68%; mean: 11.35 ± 6.19%, respective-
ly), however, the difference was statistically not sig-
nificant (p = 0.64). The control group was character-
ized by a slightly higher percentage value of CD83+
Mo-DCs with CD200R antigen expression (median:
73.22%, range 36.2–89.05%; mean: 70.24 ± 19.49%)
than laryngeal cancer patients (median: 68.64%, range
29.03–88.82%; mean: 64.28 ± 18.95%), however, the
difference was not statistically significant (p = 0.58).
No correlations were found between the measured
characteristics of cells and clinicopathological data,
presented in Table 1.
Discussion
Our study revealed that there is a significant relation-
ship between the presence of laryngeal cancer and
the expression of CD200 and CD200R molecules on
the monocyte-derived dendritic cells pulsed with au-
tologous cancer cell lysates. Unstimulated CD83+
Mo-DCs of healthy controls and patients with laryn-
geal cancer presented significantly lower MFI values
of CD200 and CD200R antigen expression than the
same type of cells after the stimulation. This finding
means that pulsing DCs with laryngeal cancer tumor
lysates would increase the known inhibitory effect of
the CD200 molecule on myeloid cells and we assess
this finding as a surprising one. Many studies pub-
lished before [10, 11] used the concept of pulsing DCs
with autologous tumor lysates to elicit an effective
antitumor immune response.
The expression of CD200 was implicated in multiple
types of human cancer including squamous cell car-
cinoma. However, the impact of tumor expression of
CD200 on tumor immunity remains poorly under-
stood and the expression of the discussed molecules
on the Mo-DCs of laryngeal cancer patients has not
been assessed before.
Wang et al. [12] generated CD200-positive mouse
plasmacytoma J558 and mastocytoma P815 cells and
found that CD200-positive tumors were often com-
pletely rejected by adoptively transferred cytotoxic T
lymphocytes (CTL) without tumor recurrence. The
same authors [12] also proved that CD200-negative
tumors were initially rejected by adoptively trans-
ferred CTL; however, the majority of tumors recurred.
Tumor expression of CD200 significantly inhibited
suppressive activity and IL-10 production by tumor-
associated myeloid cells (TAMC). Neutralization of
IL-10 significantly inhibited the suppressor activity
of TAMC, and IL-10-deficiency allowed TAMC to

































Figure 2. A diagram presenting the differences in the MFI
values of CD200 marker expression on CD83+ monocyte-
derived DCs stimulated or not stimulated with autologous
cancer cell lysates in patients with laryngeal cancer and in
control group (Mo-DCs not stimulated)
Figure 3. A diagram presenting the differences in the MFI
values of CD200R antigen expression on CD83+ monocy-
te-derived DCs stimulated or not with autologous cancer
cell lysates in patients with laryngeal cancer and in control
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prevented tumor recurrence via inhibiting IL-10 pro-
duction by TAMC [12]. Other authors implicated IL-
10 as a cytokine that might modify development/mat-
uration of DC into a population expressing increased
amounts of B7-2 co-molecule and capable of induc-
ing tolerance [13].
Patients with advanced cancer including squamous
cell carcinoma of the head and neck are known to be
immunologically compromised [14, 15]. Tumor cells
can therefore escape from the immune responses by
numerous mechanisms, including the molecule
CD200 that acts as a potent suppressor of CD200R-
expressing immune cells [16–18]. CD200 molecule or
its natural ligand play role in the delivery of a toler-
ance-inducing signal. Natural expression of CD200
was initially first described on thymic dendritic cells
[19]. Further studies revealed that CD200 positive
cells can inhibit the stimulation of type-1 cytokine
production by bone-marrow-derived B7–1 (and B7–2)
positive dendritic cells [20]. Other data also implied
an immunoregulatory role for CD200 expression, as-
sayed by altered cytokine production in vitro from
cells stimulated in the presence or absence of ex-
pressed CD200 [21], which has been nowadays wide-
ly accepted as the immunosuppressive factor. E.g.,
data presented by Gorczynski et al. [22] suggest that
CD200 was functionally important in the increased
graft survival of renal graft seen in portal venous per-
itransplant-immunized with dendritic cells from bone
marrow cultures of mice receiving renal allografts.
Increased expression of CD200 on dendritic cells was
associated with the inhibition of cytokine production
and renal allograft rejection. These authors also sug-
gested that CD200 provides a costimulator signal for
preferential IL-4 (TGF-b) production [20]. Borriello
et al. [21] also reported that CD200 provided a co-
stimulatory signal for activated murine T cells, but
was unable to increase IL-2 production.
Table 1. Patient characteristics
Total number of patients 44
Age 63.23 ± 8.85
(years) 64.5
Grading (Histological differentiation G1 Number of patients 12
of surgically resected tumour) Percentage 27.27
G2 Number of patients 19
Percentage 43.18
G3 Number of patients 13
Percentage 29.55
T classification (The size of the tumour T1 Number of patients 7
and whether it has invaded nearby tissue) Percentage 15.91
T2 Number of patients 9
Percentage 20.45
T3 Number of patients 16
Percentage 36.36
T4 Number of patients 12
Percentage 27.27
Distant metastasis Yes Number of patients 0
Percentage 0
No Number of patients 44
Percentage 100
Site of tumour Supraglottic Number of patients 20
Percentage 45.45
Glottic Number of patients 19
Percentage 43.18
Transglottic Number of patients 5
Percentage 11.36
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Furthermore, Hoek et al. [16] suggested that bind-
ing of CD200 antigen with its specific receptor
CD200R on myeloid cells such as macrophages, was
responsible for down regulation of its activity, so the
tissue damage caused by macrophages might be nat-
urally reduced. Rosenblum et al. [24] found higher
expressions of CD200 on dendritic cells that under-
went apoptosis. The most recent study, provided by
Seeds et al. [25] showed that CD200 knock-out mac-
rophages produced more IFN-a than wild-type mac-
rophages in response to stimulus, what was consis-
tent with CD200's known inhibitory effect on mye-
loid cells. In contrast, blocking CD200 with an anti-
CD200 mAb resulted in reduced IFNa production.
This suggests there could be a differential effect of
CD200 on IFN induction pathways in dendritic cells
and macrophages. These results support the hypoth-
esis that CD200 is involved in virally induced type I
IFN induction [25].
A number of monoclonal antibodies (mAbs) has
been successfully used in the treatment of solid can-
cers. Because CD200 does not have a signaling do-
main it appears that anti-CD200 Abs do not directly
affect targeted tumor cells, and Kretz-Rommel et al.
[26] demonstrated that the anti-CD200 mAbs, as ex-
pected, did not inhibit tumor cell proliferation or di-
rectly induce cell death [27]. Therefore, antagonistic
anti-CD200 Abs are expected to exert their effect by
blocking immune suppression and by potentially me-
diating antibody-dependent cellular cytotoxicity or
complement-dependent cytotoxicity. Presented stud-
ies demonstrated that a blockade of CD200 immune
suppression by anti-CD200 mAb in the presence or
absence of antibody effector function was sufficient
to achieve high antitumor activity. Our data indicate
that also dendritic cell based immunotherapy support-
ed by the use of mAb anti-CD200 may be effective in
the future treatment of laryngeal cancer, however,
further studies analyzing the effects of both mAb anti-
CD200 and anti-CD200R, and Mo-DCs on autolo-
gous laryngeal cancer cell cultures have to be per-
formed.
We showed that there was a relation between the
presence of laryngeal cancer and the expression of
CD200 and CD200R molecules on the CD83+ mono-
cyte-derived dendritic cells pulsed with autologous
cancer cell lysates. Unstimulated CD83+ Mo-DCs of
laryngeal cancer patients and healthy controls pre-
sented significantly lower MFI values of CD200 and
CD200R antigen expression than the same cell types
from laryngeal cancer patients. It seems to be expedi-
ent to conduct an analysis which would assess the in-
fluence of these glycoproteins on the clinical course of
the disease. The antibodies which are directed against
CD200 and CD200R molecules antigens can be ap-
plied in the treatment of laryngeal cancer to inhibit
the immunosuppressive activity of CD200 molecule.
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